Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience.

Özçelik, Serhat; Çelik, Mehmet; Vural, Aski; Aydin, Bünyamin; Özçelik, Melike; Gozu, Hulya

Özçelik, Serhat; Çelik, Mehmet; Vural, Aski; Aydin, Bünyamin; Özçelik, Melike; Gozu, Hulya.

Afiliação

Özçelik S; Department of Endocrinology and Metabolism, Adiyaman Training and Research Hospital, Adiyaman, Turkey.
Çelik M; Department of Internal Medicine, Division of Endocrinology and Metabolism, Antalya Kepez State Hospital, Kepez, Turkey.
Vural A; Division of Internal Medicine, Adiyaman Training and Research Hospital, Adiyaman, Turkey.
Aydin B; Department of Endocrinology and Metabolism, Adiyaman Training and Research Hospital, Adiyaman, Turkey.
Özçelik M; Department of Internal Diseases, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Gozu H; Department of Endocrinology and Metabolism, Marmara University Training and Research Hospital, Turkey.

Arch Med Sci ; 17(1): 1-8, 2021.

Article em En | MEDLINE | ID: mdl-33488849